Hong Kong Center for Neurodegenerative Diseases (HKCeND) showcased its groundbreaking advancements in the development of diagnostics and therapeutics for neurodegenerative diseases, particularly Alzheimer’s disease, at the Asia Summit on Global Health (ASGH) held on 26 and 27 May 2025, at the Hong Kong Convention and Exhibition Centre. The core team members from University College London, a valued research collaborator of HKCeND, including Prof. John Hardy, participated in this premier event. This summit highlighted the importance of collaborative efforts in advancing global healthcare.
During the inaugural plenary session titled “Shaping a More Equitable and Sustainable Health System”, Prof. Nancy Ip, President of the Hong Kong University of Science and Technology and Center Director of HKCeND, joined an esteemed panel of international leaders to address the pressing challenges facing global healthcare systems. They shared invaluable experiences and forward-looking insights to inspire the global healthcare field. Prof. Ip stated, “The complex health challenges of our time—from pandemics to workforce shortages—demand unprecedented collaboration. We must accelerate innovation-to-impact by nurturing talent, advancing translational research, and building partnerships to make quality healthcare a universal right.”
In the fireside chat titled “Dialogue with Global Pioneer in Health”, Prof. John Hardy, recognized as the “father of Alzheimer’s disease genetic studies”, shared his visionary insights into the future of neurodegenerative disease research and treatment. He highlighted that advancements in Alzheimer’s could be achieved quite quickly through improvements in earlier diagnosis and the development of innovative drugs.
ASGH, Asia’s premier event on health innovation and investment, is jointly organized by the HKSAR Government and the Hong Kong Trade Development Council. The summit serves as an exceptional platform for diverse stakeholders—including policymakers, healthcare experts, leading academic and research institutions, industry leaders, and investors from around the world—to exchange insights and explore collaborative opportunities.
At HKCeND, our team is dedicated to transforming the healthcare landscape of neurodegenerative diseases, starting with Alzheimer’s disease. We focus on developing innovative diagnostics, prognostics, and clinical interventions for neurodegenerative diseases that enhance the quality of life for the aging population worldwide.
Related News
Event